Table 1 Selection criteria for CRS + HIPC for peritoneal carcinomatosis from gastric cancer

Inclusion criteria

 − Primary or recurrent gastric adenocarcinoma

 − Histological confirmation of peritoneal carcinomatosis from gastric adenocarcinoma

 − Systemic chemotherapy and/or biological are allowed before and/or after CRS + HIPC

 − Radiotherapy is allowed before or after CRS + HIPC

 − Prior CRS + HIPC is allowed if performed more than 1 year ago

 − Age between 18 to 75 years

 − Patient Karnofsky Performance Scale (KPS) ≥ 80

 − Signed informed consent

Exclusion criteria

 − Pregnancy

 − Any malignancy other than gastric adenocarcinoma

 − Any metastatic disease other than peritoneal carcinomatosis, such as liver, pulmonary or bone metastases

 − Peritoneal carcinomatosis index (PCI) > 20 at the start of CRS

 − Impossibility to obtain complete cytoreduction (CCR-0) at the end of CRS

 − Impossibility to obtain histopathological R0 resection at the end of CRS

 − Clinical relevant ascites